Please login to the form below

Not currently logged in
Email:
Password:

Genzyme

This page shows the latest Genzyme news and features for those working in and with pharma, biotech and healthcare.

M&F Health, 90TEN and Sanofi among big winners at Communiqué Awards

M&F Health, 90TEN and Sanofi among big winners at Communiqué Awards

Sponsored by Burson Cohn &Wolfe. Winner: See Below. by Havas Lynx for Sanofi Genzyme Regeneron. ... by Havas Lynx for Sanofi Genzyme. 20. Charity, Patient or Professional Association of the Year.

Latest news

  • Oncology drives AstraZeneca, Genzyme boosts Sanofi Oncology drives AstraZeneca, Genzyme boosts Sanofi

    Meanwhile, Sanofi released its Q1 results, and its growth beat expectations, driven in part by its rare disease arm Genzyme. ... In total, Genzyme delivered a 31% sales increase, which was helped by its monoclonal antibody Dupixent.

  • Sanofi exits R&D pact with Alnylam on rare disease Sanofi exits R&D pact with Alnylam on rare disease

    Sanofi and Alnylam started working together on gene-silencing therapies in 2014, with the French drugmaker’s rare disease unit Genzyme making a $700m investment in the RNA interference specialist and ... Genzyme had previously licensed rights in 2012

  • AZ says dropping MedImmune will help ‘streamline’ its R&D AZ says dropping MedImmune will help ‘streamline’ its R&D

    Nevertheless, as MedImmune has operated as a semi-independent unit within AZ – in much the same way as Genentech within Roche and Sanofi’s Genzyme – the decision raises questions about how

  • Sanofi extends growth spurt thanks to Genzyme, Dupixent Sanofi extends growth spurt thanks to Genzyme, Dupixent

    US approval of Cablivi adds to good news. Sanofi has put a long run of decline caused by patent losses in its rear view mirror, with rare disease unit Genzyme and ... Genzyme had a solid quarter with sales up almost 11% to 794m, while Dupixent (dupilumab)

  • Havas Lynx Group scoops nine Golds at PM Society Awards Havas Lynx Group scoops nine Golds at PM Society Awards

    Meanwhile, Sanofi Genzyme and Regeneron came out on top in the pharma category, collecting five Golds and one Silver. ... Target Award for Secondary Care Advertisement: Cognite for Tillots Pharma. Innovation: Havas Lynx for Sanofi Genzyme and Regeneron.

More from news
Approximately 28 fully matching, plus 157 partially matching documents found.

Latest Intelligence

  • Trust me, I’m from pharma Trust me, I’m from pharma

    Rather than assuming anything, Sanofi Genzyme took a step back and asked patients: how can we help? ... In Sanofi Genzyme’s case, it culminated in a set of briefs that were owned by the patients living with the disease.

  • Pharma deals in July 2015 Pharma deals in July 2015

    Firstly the divestment for up to $300m to Genzyme of Caprelsa (vandetanib), an orphan drug treatment for thyroid carcinoma. ... 560+. AstraZeneca / Genzyme. Acquisition of R&D. Caprelsa (vandetanib) marketed. 300.

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Voyager Therapeutics/ Sanofi (Genzyme). Gene therapy - Parkinson's disease, Friedreich's ataxia and Huntington's disease.

  • Pharma deals during November 2014 Pharma deals during November 2014

    Cerdelga, an oral therapy for adult patients with Gaucher disease type 1, was developed by Genzyme and approved by the FDA in August this year.

  • Pharma deals during January 2014 Pharma deals during January 2014

    The now expanded deal grants Genzyme rights in all markets outside North America and Western Europe. ... In 2008 Genzyme gained rights to ataluren from PTC Therapeutics at a cost of $100m.

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

More from appointments
Approximately 4 fully matching, plus 35 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics